unless defined otherwise , all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs . although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention , the preferred methods and materials are now described . all publications mentioned hereunder are incorporated herein by reference . as used herein , chsp60 1 - 544 refers to a purified polypeptide having an amino acid sequence substantially as shown in fig2 . chsp60 1 - 544 also refers to a purified polypeptide substantially as shown in fig2 including sequence variations , for example , as shown in fig3 which do not significantly alter the immunoreactivity of the peptide as discussed herein . as used herein , “ removable fusion partner ” refers to a compound , for example , a polypeptide , which can be used in purifying a polypeptide of interest and can be separated from the polypeptide of interest using means known in the art without cleaving or otherwise modifying the polypeptide of interest so that the reactivity or functioning of the polypeptide in the intended use is compromised . as used herein , “ substantially purified ” refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated and are at least about 60 % free , preferably about 75 % free , and most preferably about 90 % free from other components with which they are naturally associated . herein described is an expression system for the production of chsp60 1 - 544 as described above and consisting of amino acids 1 - 544 of chsp60 and a fragment of chsp60 1 - 544 consisting of amino acids 80 - 277 of chsp60 , designated as chsp60 80 - 277 . specifically , the expression system is arranged so that chsp60 1 - 544 or chsp60 80 - 277 is produced as a fusion protein which can be purified based on the activity or property of the fusion partner , as described below . the fusion protein is then treated such that the fusion partner is cleaved , producing purified , chsp60 1 - 555 or chsp60 80 - 277 . as a result of this arrangement , the termini of the peptides are not blocked or masked by the fusion partner , meaning that more antigenic epitopes are available . as will be apparent to one knowledgeable in the art , given the high degree of homology between proteins of the groe family , it is very difficult to isolate purified native chsp60 using traditional_means , such as , for example , sizing columns , ion exchange columns or even antibody columns . furthermore , as discussed above , traditional tags used for isolation of recombinant proteins may mask antigenic determinants . as will be appreciated by one knowledgeable in the art , the availability of larger number of epitopes for antibody reactivity may lead to a more sensitive assay . it is also of note that the lack of a fusion partner means that the use of chsp60 1 - 544 or chsp60 80 - 277 as antigens in the elisa assays as described herein more closely correspond to those presented in vivo . furthermore , removal of the fusion partner reduces the number of assays required , allowing many more samples to be screened . also described are pcr primers for generating a dna fragment encoding the chsp60 1 - 544 protein or chsp60 80 - 277 fragment for subsequent cloning into other expression vectors and construction of these expression vectors , as described below . in one embodiment , described below , the substantially purified polypeptide consisting of chsp60 1 - 544 or chsp60 80 - 277 fragment is used in elisa assays for screening samples from patients suspected of having chlamydial infections . as will be appreciated by one of skill in the art , the presence of antibodies bound to chsp60 1 - 544 or chsp60 80 - 277 may be detected by any suitable means known in the art . as discussed herein , these may include patients having , suspected of having or at risk of developing diseases or disorders such as , but by no means limited to chronic pelvic pain , pelvic inflammation disease , tubal infertility , chronic inflammation , ectopic pregnancy , atherioscierosis , asthma , stroke , alzheimer &# 39 ; s disease , multiple sclerosis , urogenital tract infections , pneumonia , respiratory infections or other chlamydia associated autoimmune diseases . specifically , the presence of anti - chsp60 antibody indicates persistent , acute or repeated chlamydial infections which in turn indicates that the patient is at risk of developing complications , as discussed herein . as will be appreciated by one knowledgeable in the art , complications of c . pneumoniae infections can include , for example , cardiovascular diseases ( atheriosclerosis , stroke , abdominal aortic aneurysm , etc ), pulmonary diseases for example copd and asthma , as well as neurodegenerative diseases for example alzheimer &# 39 ; s disease and multiple sclerosis . [ 0037 ] chlamydia pneumoniae is one of the most common causes of respiratory infection . seroepidemiologic studies show the 50 - 80 % of adult populations worldwide has evidence of past infection . the infection is typically mild or asymptomatic and therefore remained undiagnosed or not treated . it is now recognized that c . pneumoniae can persist in the host leading to long term sequelae of cardiovascular disease , exacerbation of asthma and other chronic illnesses such as multiple sclerosis , alzheimer &# 39 ; s disease , chronic obstructive pulmonary disease . the genetic and biologic basis for susceptibility to these long term complications of c . pneumoniae infection to unknown but it is likely immune - mediated . we have shown that antibody response to a fragment of the c . pneumoniae 60 kda heat shock protein is found significantly more frequently in men with atherosclerosis and asthma compared to those without evidence of these chronic diseases . persistent ocular and genital infection with chlamydia trachomatis can lead to binding trachoma , and adverse reproductive sequelae of pelvic inflammatory disease , ectopic pregnancy and tubal infertility , respectively . antibody to the chsp60 chsp60 80 - 277 was previously used along with chsp60 - gst fusion described above to test sera of individuals with scarring trachoma for antibodies against chsp60 . compared to the gst fusion protein , the fragment showed not only an increase in the number of positive responses in the cases , but also in the controls ( peeling et al 1999 infect dis . obstet gynecol . 7 : 108 - 9 ). thus , this data indicated that chsp60 80 - 277 was of no value in analyzing individuals with scarring trachoma . however , as discussed below and as shown in tables 1 and 2 , chsp60 80 - 277 and the chsp60 1 - 544 protein show greater sensitivity and lower background compared to the chsp60 - gst fusion in samples of patients with complications of urogenital tract infections or respiratory infections . as will be appreciated by one knowledgeable in the art , other suitable fusion partners or expression systems which allow for expression and isolation of the native chsp60 1 - 544 or chsp60 80 - 277 may also be used . that is , in other embodiments , there are provided expression systems comprising a promoter operably linked to a dna molecule deduced from the amino acid sequence of chsp60 1 - 544 or chsp60 80 - 277 and a dna molecule encoding a suitable ( i . e . removable ) fusion partner . as will be appreciated by one of skill in the art , the dna encoding the fusion partner may be either 5 ′ or 3 ′ to the dna encoding the chsp60 1 - 544 or chsp60 80 - 277 . in yet other embodiments of the invention , there are provided host cells transformed with the above - described expression system , as discussed below . the invention provides kits for carrying out the methods of the invention . accordingly , a variety of kits are provided . in some embodiments , the kits include purified chsp60 1 - 544 and / or chsp60 80 - 277 and / or expression systems for producing same . in some embodiments , the kit may also include elisa reagents . the kits may be used for detecting antibodies against chsp60 in patients having , suspected of having or at risk of developing diseases or disorders such as , but by no means limited to , chronic pelvic pain , pelvic inflammation disease , tubal infertility ,, chronic inflammation , ectopic pregnancy , atheriosclerosis , asthma , stroke , alzheimer &# 39 ; s disease , multiple sclerosis , urogenital tract infections , pneumonia , respiratory infections or other chlamydia associated autoimmune diseases . as will be appreciated by one knowledgeable in the art , the kits may also include instructions for purification and / or preparation of chsp60 1 - 544 and / or chsp60 80 - 277 , as described below . the kits of the invention comprise one or more containers comprising substantially purified chsp60 1 - 544 and / or chsp60 80 - 277 or an expression system for producing same and a set of instructions , generally written instructions although electronic storage media ( e . g ., magnetic diskette or optical disk ) containing instructions are also acceptable , relating to the use intended for the purified peptides or expression system . the containers may contain unit doses , bulk packages ( e . g ., multi - dose packages ) or sub - unit doses . as will be appreciated by one knowledgeable in the art , samples from a variety of sources as discussed herein may be screen using the described kits . the substantially purified chsp60 80 - 277 fragment or chsp60 1 - 544 of the kit may be packaged in any convenient , appropriate packaging . for example , if there is a freeze - dried formulation , an ampoule with a resilient stopper is normally used , so that the peptide may be easily reconstituted by injecting fluid through the resilient stopper . the following examples are provided to illustrate , but not limit , the invention . the bacterial isolates used in the present invention were from a laboratory collection . all cultures were grown in minimal essential media supplemented with 10 % fetal bovine serum , 2 mm l - glutamine , 25 μg / ml gentamycin , 100 μg / ml vancomycin , and 1 μg / ml cycloheximide . high molecular weight genomic dna was isolated by sds / proteinase k digestion at 56 ° c . for 3 hours followed by phenol / chloroform extraction and ethanol precipitation . dna concentration was determined by uv spectroscopy , at a 260 and purity estimated by the a 260 / a 280 ratio . the deoxyribonucleotide triphosphates datp , dctp , dgtp , dttp are added to the synthesis mixture , either separately or together with the primers , in adequate amounts and the resulting solution is heated to 95 ° c . for 5 minutes . after this heating period , the solution is subjected to 35 cycles of 1 minute at 95 ° c ., 1 minute at 55 ° c ., 1 . 5 minutes at 72 ° c . following the final cycle , the solution was held at 72 ° c . for 10 minutes , and then cooled to 4 ° c . the agent used for the polymerase chain reaction ( pcr ) was taq dna polymerase , purchased from gibco life technologies . the following pcr conditions were used : 50 mm kcl , 10 mm tris , ph 8 . 4 , 1 . 5 mm mgcl 2 , 200 μm of each dntp ( all final concentrations ), 50 ng of genomic dna , 2 . 5 u of taq dna polymerase ( gibco ) and 0 . 5 μm of each of the degenerate primers mh279 and mh280 , and clh1 and clh2 , described below . a final volume made up to 50 μl with dh 2 o was used . the sequences of the primers used to amplify the chsp60 protein fragment encompassing amino acids 80 - 277 from c . trachomatis , c . pneumoniae , and c . psittaci are as follows : mh279 : 5 ′ aaa act cat atg aaa gcw ggv gay gga acy aca aca 3 ′ mh280 : 5 ′ cat agc tgc tct tcc gca wcc raa vcc wgg agc ttt mac wgc 3 ′ it is of note that these degenerative primers have been used previously ( goh et al , 1996 , j clin micro 34 : 818 - 823 ) for generating a dna fragment used as a species - specific probe for identifying different hsp60 genes . the sequences of the primers used to amplify the dna encoding chsp60 1 - 544 protein from c . trachomatis , c . pneumoniae , and c . psittaci are as follows : clh1 : 5 ′ agm rca cat atg gym gck aaa aay att aaa tay aa 3 ′ clh2 : 5 ′ twr twc ygc tct tcc gca yta rta gtc cat tcc tgc gcy wg 3 ′. it is of note that the 5 ′ end sequences of mh279 and clh1 contain an ndei restriction site , while the 3 ′ end sequences of mh280 and clh2 contain a sapi restriction site . the amplified pcr products were digested with ndei and sapi and then ligated into pcyb1 . the recombinant plasmids were transformed into competent e . coli and screened and selected . [ 0059 ] escherichia coli jm109 containing the pcyb1 plasmids encoding the chsp60 1 - 544 protein and the chsp60 80 - 277 protein were generated using the new england biolabs ™ impact i kit . expression and purification of the chsp60 proteins were performed according to established protocols for the impact i ( intein mediated purification with an affinity chitin - binding tag ) kit . the impact i system utilizes a protein splicing element , an intein , from saccharomyces cerevisiae vma1 gene . the intein has been modified such that it undergoes a self - cleavage reaction at its n - terminus at low temperatures in the presence of thiols such as 1 , 4 - dithiothreitol ( dtt ), β - mercaptoethanol or cysteine . the gene / nucleic acid encoding the target protein / protein fragment is inserted into a multiple cloning site ( mcs ) of the pcyb1 vector to create a fusion between the c - terminus of the target gene and the n - terminus of the gene encoding the intein . the dna encoding a small 5 kda chitin binding domain ( cbd ) from bacillus circulans has been added to the c - terminus of the intein for affinity purification of the 3 part fusion , shown schematically in fig4 . when crude extracts of cells from an inducible e . coli expression system are passed through a chitin column , the fusion protein binds to the chitin column while all other contaminants are washed through the column . the fusion is then induced to undergo an intein - mediated self - cleavage on the column by overnight incubation at 4 ° c . in the presence of dtt or β - mercaptoethanol . the target protein is released while the intein - chitin binding domain fusion partner remains bound to the column . a 10 ml culture of lb broth containing 100 μg / ml ampicillin was inoculated with a freshly grown colony of the e coli clone to be cultured . the culture was then incubated at 37 ° c . overnight with shaking . the overnight culture was used to inoculate a 1 l flask of lb , which was then grown at 37 ° c . with shaking to od 600 of 0 . 6 - 0 . 8 . iptg was added to the culture to a final concentration of 0 . 7 mm and the culture was transferred to 30 ° c . the culture was incubated for a further 3 hours with moderate shaking . the cells were then spun down from the culture at 5000 × g for 15 minutes at 4 ° c . and the supernatant was discarded . the pellet was resuspended in 10 ml of ice - cold column buffer ( 2 . 42 g tris - hcl , 29 . 22 g nacl , 0 . 0372 g edta , 1 ml triton x - 100 per litre ) and the cells were lysed by sonication on ice . the lysed cells were centrifuged at 12 , 000 × g for 30 minutes and the pellet was discarded . the supernatant was loaded onto a chitin column at a rate of approximately 1 drop per second at 4 ° c . the column was then washed with 200 ml of column buffer at a flow rate of one drop per second at 4 ° c . all traces of the cell extract were washed off the sides of the column . the column was then quickly flushed with 30 ml of cleavage buffer ( 2 . 42 g tris - hcl , 2 . 92 g nacl , 0 . 0372 g edta per litre ) containing 30 mm dtt at 4 ° c . the column flow was stopped when almost all of the cleavage buffer had passed through the column . the column was left at 4 ° c . overnight . the target protein was eluted from the column using 20 ml of cleavage buffer without dtt and 1 ml fractions were collected . the fractions were stored at − 20 ° c . fractions were analyzed by bradford assay , sds - page and western blotting using anti - chsp60 antibodies . the eluted fractions were dialyzed against 5 litres of pbs for 4 hours at 4 ° c . the pbs was replaced and the protein fractions were dialyzed overnight at 4 ° c . the enzyme - linked immunosorbant assay ( elisa ) was performed as follows . one hundred microliters of chsp60 protein ( 10 ng ) was added to each well of a 96 - well microtiter plate and allowed to adsorb for 3 hours at 37 ° c . or overnight at 4 ° c . the unbound antigen was washed from the plate and discarded , and the wells were blocked with 150 μl of 3 % bovine serum albumin ( bsa ) in pbs for 90 minutes . the plates were then washed and 100 μl of patient sera ( 1 : 500 dilution in pbs containing 0 . 5 % bsa and 0 . 2 % tween 20 ) was added and incubated for 60 minutes at 37 ° c . the wells were then washed three times with pbs containing 0 . 2 % tween 20 , and then 100 μl of horseradish peroxidase - conjugated goat anti - human immunoglobulin antibody ( 1 : 4000 ) was added to each well and incubated for 60 minutes at 37 ° c . the wells were then washed three times with pbs containing 0 . 2 % tween 20 and then bound antibody was detected by the addition of 100 μl of substrate ( 4 mg of 2 , 2 ′- azino - bis [ 3 - ethyl - benz - thiazoline - 6 - sulfonate ]/ ml in 0 . 1 m citric acid buffer , ph 4 . 2 and 10 μl hydrogen peroxide ). the plates were then developed in the dark for 20 minutes and the optical density of each well was read in an elisa reader at 405 nm . all sera were assayed in duplicate against the chsp60 protein with one negative control serum and 2 positive control sera included with each plate . to determine the threshold for a positive antibody response , all chsp60 protein preparations were tested against a panel of 50 chlamydia - seronegative sera . the threshold is defined as the mean of the response of these negative sera plus three standard deviations from the mean . results are summarized in table 1 . similarly , chsp60 antibodies in asthma cases and nonasthmatic controls who were cpn seroreactive were tested for reactivity to chsp60 - gst and chsp 80 - 277 , as shown in table 2 . patients undergoing carotid endarectomy for significant symptomatic stenosis (& gt ; 60 %) were enrolled in the study after informed consent . the demographic features and results of immunohistochemical staining for c . pneumoniae , cytomegalovirus and herpes simplex type i were previously reported ( chiu et al , 1997 ). immunohistochemical staining was performed on paraffin embedded sections by the labeled ( strep ) avidin - biotin - peroxidase method . the antisera used included c . pneumoniae specific rr - 402 and cf2 monoclonal antibodies . sera were diluted 1 : 500 and tested against a purified recombinant fragment of chsp60 ( amino acids 80 - 277 ) as antigen in a standard elisa as described previously ( toye et al , 1993 , j . infect dis 168 : 1236 - 1240 ) and as described above . chlamydia serology was performed by the micro - immunofluorescence ( mif ) method to detect igm and igg antibodies to purified elementary bodies of chlamydia species of c . pneumoniae , c . trachomatis and c . psittaci . ( wang , 1999 , in chlamydia pneumoniae : the lung and the heart , allegra and blasi , eds , springer - verlag italia : milano ) sera were screened at 1 : 16 dilution and all positive sera were titered to end point . [ 0070 ] c . pneumoniae antigen was detected by immunohistochemical staining in 54 ( 72 %) of 75 carotid atheromatous plaques . of the 54 patients with detectable c . pneumoniae antigen , the mean od was 0 . 19 ± 0 . 15 and in the 21 patients without c . pneumoniae antigen the od was 0 . 11 ± 0 . 08 , p = 0 . 01 ( 2 tailed ). for chsp - 60 igg antibody reactivity ≧ 0 . 12 od , 38 ( 70 . 4 %) of 54 patients with c . pneumoniae antigen in atheromas had anti - chsp - 60 , versus 5 ( 23 . 8 %) of 21 patients without c . pneumoniae antigen , p & lt ; 0 . 001 . none of the patients had igm antibodies and 80 % of the total cohort had detectable igg antibodies to c . pneumoniae (& gt ; 1 ; 16 ), suggesting a history of c . pneumoniae infection . there was poor correlation between mif serology and c . pneumoniae antigen detection ( previously reported in chiu et al , 1997 ). there was also lack of correlation with serology and chsp - 60 antibodies , suggesting that the chsp60 antibody response is not just a marker of past infection but is uniquely associated with the presence of c . pneumoniae in the atheromas , and possibly with the development of atherosclerosis . c . pneumoniae c . pneumoniae ( ag positive ) ( ag negative ) ( n = 54 ) ( n = 21 ) p value anti - chsp - 60 0 . 19 ± 0 . 15 0 . 11 ± 0 . 08 0 . 01 ( mean od ± sd ) od ≧ 0 . 12 38 ( 70 . 4 %) 5 ( 23 . 8 %) & lt ; 0 . 001 example viii - discussion atherosclerosis involves a low grade chronic inflammatory process ( ross , 1999 ; alexander , 1994 ; munro and cotran , 1988 ), and circulating markers of inflammation such as crp , fibrinogen , serum amyloid a protein and serum proinflammatory cytokines are predictors of current cardiovascular disease or future myocardial infarction ( danesh et al , 1998 , jama 279 : 1477 - 1482 ; ridker , 1999 , am intern med 130 : 933 - 937 ; koenig et al , 1999 , circulation 99 : 237 - 242 ; kuller et al , 1996 , am j epid 144 : 537 - 547 ). it has been postulated that these circulating markers of inflammation may possibly be associated with the presence of infectious agent ( s ), such as c . pneumoniae , playing a role in atherogenesis . a recent study of patients with coronary artery disease ( n = 302 ) and seropositive for c . pneumoniae (≧ 1 : 16 igg titer ), demonstrated a reduction in global tests of 4 inflammatory markers ( crp , il - 1 , il - 6 and tnfα ) 3 months after the completion of a 3 month regimen of azithromycin ( anderson et al , 1999 , circulation 99 : 1538 - 1539 ). in a study from finland , part of the 8 . 5 year trial in the helsinki heart study , the independent and joint effects of infections and inflammation were studied in a nested case : control design ( roivainen et al , 2000 , circulation 101 : 252 - 257 ). both c . pneumoniae and herpes simplex virus - i antibodies were associated with increased risk for coronary artery disease . one of the mechanisms by which c . pneumoniae may be involved in the pathogenesis of atherosclerosis is through chlamydial heat shock protein . it has been postulated that molecular mimicry of chsp - 60 with human hsp60 may induce an autoimmune reaction , leading to activation of inflammatory pathways and an increase in concentration of inflammatory markers ( mayr et al , 1999 , circulation 99 : 1560 - 1566 ). specifically , the homology between the amino acid sequence of the 80 - 277 fragment and the corresponding human hsp60 fragment is 50 %. our results suggest that immune response against epitopes within this region of the chlamydial hsp60 may have elicited an autoimmune response due to cross - reactivity to epitopes of the human hsp - 60 . it is also of note that patients with c . pneumoniae antigen in atheromatous plaques have significantly higher levels of chsp - 60 antibodies than those without detectable antigen . furthermore , chsp - 60 localizes in human atheroma and regulates tnfα and matrix metalloprotease expression ( kol et al , 1998 ), factors that are considered atherogenic . in addition , chsp - 60 is able to activate human vascular endothelium , smooth muscle cells and macrophages ( kol et al , 1999 , j clin invest 103 : 571 - 577 ), and in vitro it can stimulate low density lipoprotein ( ldl ) cellular oxidation ( kalayoglu et al , 1999 , j infect dis 180 : 780 - 790 ), the major harmful component of ldl . recently , it was also been shown that serum antibodies to chsp - 60 cross - react with human hsp - 60 and mediate endothelial cytotoxicity , a key event in pathogenesis of atherosclerosis ( mayr et al , 1999 ). in summary , chsp - 60 antibody levels are correlated with the presence of c . pneumoniae antigen in atheromas and may play a role in the pathogenesis of atherosclerosis . while the preferred embodiments of the invention have been described above , it will be recognized and understood that various modifications may be made therein , and the appended claims are intended to cover all such modifications which may fall within the spirit and scope of the invention . [ 0076 ] table 2 chsp60 antibodies versus hsp60 ( cpn fragment ) antibodies in asthma cases and nonasthmatic controls who were cpn seroreactive ( mif igg 1 : 16 ) study group no . findings all subjects 143 chsp60 v hsp60 ( cpn ) r = 0 . 012 , p = . 889 pearson r = 0 . 068 , p = . 356 spearman chsp60 v fev1 / fvc % r = − 0 . 17 , p = . 13 pearson pred hsp60 ( cpn fragment ) v r = −. 24 , p = . 02 pearson fev1 / fvc % pred chsp60 ( gst fusion ) o . d . × 1000 ( sd ) p - value * asthma 91 131 ( 207 ) controls 52 94 ( 154 ) . 82 hsp60 ( cpn frag ) o . d . × 1000 ( sd ) p - value * asthma 91 156 ( 115 ) controls 52 114 ( 57 ) . 03 pro lys gly arg his val val ile asp lys ser phe gly ser pro gln glu ala ile tyr xaa glu gly leu arg asn val thr ala gly ala asn pro met asp leu lys arg gly ile asp lys ala xaa lys val val val ala gln val ala thr ile ser ala asn asn asp xaa glu ile gly asn leu ile ala glu ala met glu lys val gly lys asn gly ser ile thr met asn phe asn arg gly tyr leu ser ser tyr phe xaa thr asn pro glu thr gln glu cys val leu glu xaa ala leu xaa leu ile tyr asp lys lys ile ser gly ile lys asp phe leu pro xaa leu gln gln val leu thr asn glu asp glu gln ile gly ala arg ile val leu lys ala ala ile ile phe gln gln val met ser arg ser ala asn glu gly tyr
an expression system for production of full - length chlamydial heat shock protein 60 and an immunore - active subfragment thereof is described . the expression system is arranged such that the chsp60 or fragment is initially isolated as a fusion protein which is then cleaved off , leaving purified chsp60 .